Magzter GOLD ile Sınırsız Olun

Magzter GOLD ile Sınırsız Olun

Sadece 9.000'den fazla dergi, gazete ve Premium hikayeye sınırsız erişim elde edin

$149.99
 
$74.99/Yıl

Denemek ALTIN - Özgür

"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"

BioSpectrum Asia

|

June 2024

Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.

- Dr Manbeena Chawla

"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"

These expansions are strategically aimed at serving a diverse range of industries, including biopharma, pharmaceuticals, and the food sector. In a recent interview with BioSpectrum, Manas Kumar, Global Director Pharma & Director Strategic Marketing and Business Development- APAC at Lindström Oy, India sheds light on the company's ambitious growth plans and its commitment to sustainability. Edited excerpts:

Lindström has recently opened a larger cleanroom facility at Hyderabad in India. How do you plan to increase your presence in the Indian workwear services market with respect to the pharma and healthcare industry?

We're thrilled about our leadership in workwear and cleanroom services, especially in Hyderabad, India's bustling pharma hub. Our recent moves, like opening our second top-notch cleanroom facility and relocating to a bigger, modern workwear spot in Telangana, show just how committed we are to this vibrant region. It's all part of our big plans to solidify our place as forerunner in the global textile services sector. We're talking about investing in cutting-edge facilities and expanding our capacity to meet the growing needs of industries like biopharma, pharma, and more.

Our new facility is a significant milestone in our growth journey. Doubling our workwear capacity in Telangana means we're ready to tackle the rising demand for top-quality workwear in the biopharma and pharma sectors.

Speaking of numbers, we've got 11 workwear and 2 cleanroom units across India, managing a whopping 2.5 million garments in circulation thanks to our amazing team of over 900 employees. This feeds into our global portfolio of 21 million textiles, showcasing our extensive reach and capabilities in 24 countries across Europe and Asia.

BioSpectrum Asia'den DAHA FAZLA HİKAYE

BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

time to read

1 min

BioSpectrum Asia Oct 2025

BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

time to read

1 min

BioSpectrum Asia Oct 2025

Listen

Translate

Share

-
+

Change font size